Iterum Therapeutics plc
ITRM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $30,687 | $39,736 | $41,894 | $34,867 |
| - Cash | $11,002 | $13,026 | $12,652 | $24,125 |
| + Debt | $0 | $32,558 | $32,025 | $45,534 |
| Enterprise Value | $19,685 | $59,268 | $61,267 | $56,276 |
| Revenue | $390 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $370 | -$696 | -$342 | $0 |
| % Margin | 94.9% | – | – | – |
| EBITDA | -$8,051 | -$5,650 | -$3,948 | -$5,422 |
| % Margin | -2,064.4% | – | – | – |
| Net Income | -$8,979 | -$6,509 | -$4,891 | -$6,582 |
| % Margin | -2,302.3% | – | – | – |
| EPS Diluted | -0.2 | -0.16 | -0.14 | -0.25 |
| % Growth | -25% | -14.3% | 44% | – |
| Operating Cash Flow | -$7,848 | -$4,751 | -$3,060 | -$4,256 |
| Capital Expenditures | -$13 | $0 | -$2 | $0 |
| Free Cash Flow | -$7,860 | -$4,751 | -$3,062 | -$4,256 |